Invivyd Inc. (formerly Adagio Therapeutics Inc.) has generated multiple next-generation candidate antibodies for the prevention and treatment of COVID-19, including two molecules designated for near-term clinical development in combination as NVD-200.
Pretzel Therapeutics Inc. has launched with a $72.5 million series A financing to pioneer novel therapies to modulate mitochondrial function to treat rare genetic diseases and common diseases of aging.
Previous research has revealed that some downstream hormones or effectors of the hypothalamic-pituitary (HP) unit, such as glucocorticoids, estrogen and progesterone, are elevated in patients with cancer. It was also shown that these hormones regulate the function of immune cells in the tumor microenvironment, suggesting that the neuroendocrine system and HP unit might modulate tumor immunity. In the current study, researchers from the University of Science and Technology of China aimed to investigate the role of HP unit in tumor immunity.
Researchers from Boston Children’s Hospital and Harvard Medical School reported the discovery and preclinical evaluation of SP1-77, a novel humanized monoclonal IgG-κ antibody targeting the receptor-binding-domain (RBD) of spike (S) glycoprotein of all SARS-CoV-2 variants.
Researchers from Shaperon Inc. presented positive preclinical data for their clinical-stage candidate, sodium taurodeoxycholate (HY-209), demonstrating its therapeutic potential for atopic dermatitis.
A new generation of chimeric antigen receptor (CAR) T-cell therapies with advanced functions could hold the answer to improved safety and efficacy for these effective but potentially dangerous cancer therapies, shows research led by Boston University. The scientists showed it is possible to add ‘on’ or ‘off’ switches to CAR T cells, which can be activated using oral drugs with a known safety profile.
A new vaccine that uses the native-like HIV-1 envelope (Env) trimer CH505 and a Toll-like receptor (TLR) 7/8 agonist adjuvant, successfully evaluated in macaques, generated potent polyclonal neutralizing antibodies (nAbs) and a high protection against the infection of the homologous simian-human immunodeficiency virus (SHIV).
Galecto Biotech AB has discovered β-D-galactopyranose compounds acting as galectin-1 (LGALS1) and/or galectin-3 (LGALS3) inhibitors reported to be useful for the treatment of cancer, autoimmune disease, fibrosis and cardiovascular, eye, metabolic, cerebrovascular and inflammatory disorders, among other disorders.
Qilu Regor Therapeutics Inc. has identified (hetero)arylamino-cyclohexyl-sulfonyl derivatives acting as C-C chemokine receptor type 6 (CCR6) antagonists reported to be useful for the treatment of inflammatory bowel disease, Crohn's disease and ulcerative colitis.
RSS
